Early trial results suggest tocilizumab significantly improves outcomes for critically ill COVID-19 patients



The rheumatoid arthritis drug tocilizumab significantly improves outcomes for critically ill patients with severe COVID-19, early findings from the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia have suggested.



Source link

Share and Enjoy !

0Shares
0 0
Close